Onkologie. 2015:9(4):167-170

Significance of RAS testing in colorectal cancer

Jaroslava Barkmanová1, Libor Staněk2
1 Onkologická klinika 1. LF UK, VFN a ÚVN v Praze
2 Ústav patologie 1. LF UK a VFN v Praze

Colorectal cancer is a very serious world-wide spread disease with high incidence and mortality. We try to find the predictive and prognostic

factors based on the progress in molecular oncology diagnostics to pursuit the most effective therapy for patients with CRC. RAS

mutations work as negative predictors. Molecular testing of tumors for all activating mutations in KRAS and NRAS before considering

anti-EGFR therapy is therefore essential in selecting the group of eligible patients for this treatment in metastatic colorectal cancer.

Keywords: colorectal cancer, RAS testing, KRAS and NRAS mutations, anti-EGFR therapy

Published: September 18, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Barkmanová J, Staněk L. Significance of RAS testing in colorectal cancer. Onkologie. 2015;9(4):167-170.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.svod.cz
    2. Dienstmann et al J Clin Oncol 2014; (suppl; abstr 3511)32: 5. Go to original source...
    3. Dundr P, Staněk L. Molekulární diagnostika u kolorektálního karcinomu, Farmakoterapie monografie 2013.
    4. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708. Go to original source... Go to PubMed...
    5. Spano JP, et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005; 6(2): 189-194. Go to original source...
    6. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93(14): 1062-1074. Go to original source... Go to PubMed...
    7. Van Cutsem E, Köhne C-H, Láng I, et al. Cetuximab plus irinotecan, fluorouracil and leucovorin as first line treatment for metastatic colorectal cancer: updated analysis of overal survival according to tumour KRAS and BRAF mutation status J Clin Oncol 2011; 29: 2011-2019. Go to original source... Go to PubMed...
    8. Staněk L. [Polymerase chain reaction: basic principles and applications in molecular pathology]. Cesk Patol. 2013; 49(3): 119-21. Czech. Go to PubMed...
    9. Tomášek J., Berkovcová J. Nový prediktivní molekulární marker RAS umožňuje přesnější indikaci inhibitorů EGFR v léčbě metastatického kolorektálního karcinomu. Farmakoterapie 2013; 9(6): 557-668.
    10. Bokemeyer C, et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 2014; (Suppl; abstr 3505) 32: 5. Go to original source... Go to PubMed...
    11. Lezama M, Valera J. Impact of cetuximab in current treatmentof metastatic colorectal cancer. Expert Opin. Biol. Ther. 2014; 14(3): 387-399. Go to original source... Go to PubMed...
    12. Van Cutsem E, et al. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer, ASCO, ESMO 2014, J Clin Oncol Jan 2015; 59: 4812 Go to original source...
    13. Pekin D, Normand C, Kostopoulos S, et al. Detection and quantification of minority subclones of KRAS on metastatic colorectal cancers by digital microfluidics: Therapeutic implications. Cancer Res, 2013; 73(Abstr 4211). Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.